Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage.
Furthermore, the effectiveness of radiotherapy or chemotherapy for the treatment of this tumor is not properly defined, as they are massive in size and might involve adjacent visceral organs and critical structures. However, affected population who received adjuvant chemotherapy showed survival benefits and improvement, as compared to patients who underwent surgery alone. In the case of surgeries, sometimes, preoperative radiation is given to shrink the tumor. This allows smaller doses of radiation to a smaller field and make the surgery technically more feasible. The European Organisation for Research and Treatment of Cancer (EORTC) is currently conducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiation therapy) of pre-operative radiation therapy with short-course radiotherapy, followed by surgery to direct surgery alone. Thus, continuous researches that are being conducted for the development of treatment for this disease is expected to create lucrative opportunities in the retroperitoneal liposarcoma treatment market during the forecast period.
Retroperitoneal Liposarcoma Treatment Market – Drivers
The global retroperitoneal liposarcoma treatment market is expected to exhibit a moderate growth rate, owing to low incidence of this disease across the globe. According to the World Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and is classified as a rare disease, which accounts for around 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore, rising incidence of genetic disorders is one of the major factors responsible for the global retroperitoneal liposarcoma treatment market growth. According to a report published by the Genetics Education Center, University of Kansas Medical Center, around 15% of all the cancers have an inherited susceptibility and around 12% of the hospital admissions in the U.S. accounted for the treatment of genetic causes in 2013. Various other factors contributing to market growth include changing lifestyle and growing awareness among populace regarding availability of treatment for liposarcoma through initiatives undertaken by various organizations. For instance, Liposarcoma Genome Project initiative by Massachusetts General Hospital Cancer Center conducted research to understand the differences between well-differentiated and de-differentiated liposarcoma, to support the development of treatment for the rare disease. However, high costs associated with the treatment procedures and low accessibility of the treatment due to rareness of the disease are expected to be factors hindering the market growth.
Retroperitoneal Liposarcoma Treatment Market - Regional Analysis
On the basis of region, the global retroperitoneal liposarcoma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for retroperitoneal liposarcoma treatment, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas. Furthermore, Asia pacific also generates the significant value in retroperitoneal liposarcoma treatment market, owing to the presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India around 35% of the patients suffering from sarcoma died due to dedifferentiated liposarcoma.
Retroperitoneal liposarcoma Treatment Market – Competitor Landscape
Increasing regulatory approvals by the U.S. FDA for various products manufactured by large companies is expected to boost the overall growth of the retroperitoneal liposarcoma treatment market. For instance, in 2015, the U.S. FDA granted priority review for the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured by Janssen Research & Development, LLC to treat patients with advanced soft tissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in 77 countries, within North America, Europe, South America, and Asia. Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for its in-house developed anticancer agent Halaven (eribulin mesylate) for the treatment of patients suffering from soft tissue sarcoma.
Market players operating in the global retroperitoneal liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories, and Zydus Cadila.
Retroperitoneal liposarcoma Treatment Market Taxonomy
The global retroperitoneal liposarcoma treatment market is segmented on the basis of chemotherapy treatment, type, distribution channel, and region.
By Chemotherapy Treatment:
- Combinational Therapies
- Other Chemotherapies
- Well-Differentiated Liposarcoma
- Dedifferentiated Liposarcoma
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East